Sepsis & infection

Precision Immunotherapy to Improve Sepsis Outcomes: The ImmunoSep Randomized Clinical Trial

JAMAPublished Randomised controlled trial

Primary result · SOFA decrease ≥1.4 pointsResult — go to the resultDifference 17.2% 95% CI 6.8%–27.2%

Authors' conclusion

Among patients with sepsis, precision immunotherapy targeting macrophage activation-like syndrome and sepsis-induced immunoparalysis improved organ dysfunction by day 9 compared with placebo.

Study context

Population
Adults with sepsis (Sepsis-3) due to community- or hospital-acquired pneumonia, ventilator-associated pneumonia or bacteremia, with macrophage activation-like syndrome (ferritin >4420 ng/mL) or sepsis-induced immunoparalysis (ferritin ≤4420 ng/mL and <5000 HLA-DR receptors on CD45/CD14 monocytes)276 analysed
Participants
281 adults
Comparison
Standard care + precision immunotherapy vs standard care + placebo
  • Precision immunotherapyn = 131
  • Placebon = 145reference
Primary endpoint
Decrease of ≥1.4 points in mean Sequential Organ Failure Assessment (SOFA) score from baseline
Follow-up
Day 9
Methodological detailsdouble-blind, double-dummy, placebo-controlled, multinational (6 countries), Enrolment August 5, 2021; last follow-up April 29, 2024
  • Double-blind
  • Double-dummy
  • Placebo-controlled
  • Multinational (6 countries)
  • Enrolment August 5, 2021; last follow-up April 29, 2024

Primary result

SOFA decrease ≥1.4 points

Difference

17.2%

95% CI 6.8%–27.2%

P = 0.002

Events by treatment group

Precision immunotherapy vs Placebo
difference 17.2% (95% CI 6.8%–27.2%); P = 0.002

As reported in the abstract

Secondary outcomes

28-day mortality

Not statistically significantly different between groups

Safety

Serious treatment-emergent adverse events, total
1069 (88.8%)
Increased incidence of anemia in the anakinra group
Increased incidence of hemorrhage in the recombinant human interferon gamma group

Original publication

Precision Immunotherapy to Improve Sepsis Outcomes: The ImmunoSep Randomized Clinical Trial. JAMA. Published 3 March 2026. doi:10.1001/jama.2025.24175

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.